News & Updates
Filter by Specialty:
GLP-1RAs reduce weight in overweight/obese individuals without diabetes
Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) results in significant weight loss in patients with obesity or overweight without diabetes, a study has shown. In addition, the best GLP-1RA agent appears to be semaglutide, showing superior efficacy and low-to-moderate risk of side effects.
GLP-1RAs reduce weight in overweight/obese individuals without diabetes
30 Sep 2023
Use of 5αRI does not increase cardiovascular risk in men with BPH
Treatment with five-alpha reductase inhibitors (5αRIs) does not appear to elevate the risk of hospitalization for heart failure (HF), myocardial infarction (MI), stroke, or cardiovascular death among men with benign prostatic hyperplasia (BPH), a study has shown.
Use of 5αRI does not increase cardiovascular risk in men with BPH
30 Sep 2023
Lorundrostat may expand treatment toolbox for uncontrolled hypertension
Aldosterone synthase inhibition with lorundrostat confers substantial blood pressure (BP)-lowering benefit in people with uncontrolled hypertension, while having a favourable safety profile, according to data from the phase II Target-HTN trial.
Lorundrostat may expand treatment toolbox for uncontrolled hypertension
29 Sep 2023
Drug monitoring may prevent weight gain in ASD patients taking aripiprazole
A recent study exploring the relationship between aripiprazole pharmacokinetics (PK), side effects, and effectiveness in children and adolescents with autism spectrum disorder (ASD) has found that higher plasma levels correlate with greater weight gain.